Most cancers is a giant a part of Ipsen’s development technique, evident in a collection of enterprise offers struck by the corporate lately to increase its oncology portfolio and drug pipeline. An Ipsen employee who allegedly profited from inventory transactions based mostly on private information of his employer’s $247 million buyout of a most cancers drug developer has now been charged with insider buying and selling.
The Securities and Change Fee on Tuesday filed a criticism in opposition to Ipsen worker Dishant Gupta. Gupta has agreed to plead responsible, in keeping with a separate courtroom submitting. The financial penalty has but to be determined. The U.S. Lawyer’s Workplace for the District of Massachusetts has additionally filed felony expenses in opposition to Gupta for his alleged conduct.
Paris-based Ipsen maintains U.S. operations in Cambridge, Massachusetts. In early 2022, Ipsen began speaking with Epizyme about buying that Cambridge-based firm’s drug, Tazverik, in keeping with the SEC criticism. Tazverik received FDA approval in 2020 for the remedy of follicular lymphoma. Negotiations between Ipsen and Epizyme progressed from a possible acquisition of the most cancers drug to a buyout of your complete biotech firm. The Epizyme acquisition was introduced on June 27, 2022.
Gupta lives in New Jersey and sometimes labored from house, the SEC stated within the criticism. He’s director of information technique and operations, a task that entails the advertising and strategic pricing of merchandise. By this place, Gupta allegedly realized in regards to the market potential and advertising technique for a drug that gave the impression to be Tazverik.
Within the months main as much as the acquisition announcement, the SEC stated Gupta ran quite a few web searches utilizing the phrases “Epizyme buyout” and “Epizyme takeover.” 9 days earlier than the deal was introduced, Gupta searched the phrase “Ipsen acquired Epizyme,” in keeping with the criticism. Whereas the businesses negotiated the transaction, Gupta allegedly amassed Epizyme shares. From April to June of 2022, the criticism notes that Gupta bought Epizyme inventory on 27 totally different days.
“Whereas Gupta constructed a place in Epizyme all through this era, he was most aggressive within the weeks main as much as the announcement,” the SEC stated within the criticism. “Particularly, between June 16, 2022, and June 24, 2022, Gupta bought roughly 200,000 shares, spending practically $160,000.”
The acquisition announcement got here within the early morning hours of June 27, timed to occur forward of the inventory market open in Europe. By 9:30 am Jap time, Gupta had offered all of his Epizyme shares for a revenue of $260,078.27, the SEC stated.
The SEC criticism, filed within the U.S. District Courtroom for the District of Massachusetts, is case quantity 24-cv-12316. In line with a courtroom submitting, Gupta has entered a written settlement to plead responsible to 1 rely of securities fraud. He should surrender the cash he gained illegally and likewise pay a civil tremendous. Per phrases of the plea, Gupta is barred from serving as an govt or director of any publicly traded firm. The phrases of this settlement are nonetheless topic to courtroom approval.
Oncology merchandise are the most important driver of income for Ipsen, accounting for greater than €2.3 billion of the corporate’s €3.1 billion in 2023 gross sales. In addition to the deal that introduced the corporate Tazverik, Ipsen had acquired the accredited Merrimack Prescribed drugs pancreatic most cancers drug, Onivyde. the corporate has additionally struck offers for packages nonetheless in growth. In July, Ipsen reached an settlement for world rights to a Section 1-ready antibody drug conjugate (ADC) from Foreseen Biotechnology. That deal adopted the April acquisition of world rights to an ADC from Sutro Biopharma. Ipsen’s oncology curiosity extends to different forms of medication. In 2022, months after the Epizyme acquisition, Ipsen started a partnership with Marengo Therapeutics centered on the R&D of T cell receptor therapies for most cancers.
Photograph: zoom-zoom, Getty Photographs
